|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 489.31 USD | +1.08% |
|
+0.68% | +38.68% |
| Capitalization | 21.07B 18.11B 16.97B 15.81B 29.21B 1,896B 31.77B 198B 76.62B 896B 79.07B 77.38B 3,274B | P/E ratio 2025 * |
18.1x | P/E ratio 2026 * | 17.2x |
|---|---|---|---|---|---|
| Enterprise value | 18B 15.47B 14.49B 13.51B 24.95B 1,620B 27.14B 170B 65.46B 765B 67.55B 66.11B 2,797B | EV / Sales 2025 * |
5.61x | EV / Sales 2026 * | 4.92x |
| Free-Float |
58.58% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: United Therapeutics Corporation
| 1 day | +1.08% | ||
| 1 week | +0.68% | ||
| Current month | +0.68% | ||
| 1 month | +7.78% | ||
| 3 months | +22.17% | ||
| 6 months | +50.18% | ||
| Current year | +38.68% |
| 1 week | 470.13 |  | 489.94 |
| 1 month | 445.81 | | 492.62 |
| Current year | 266.98 | | 492.62 |
| 1 year | 266.98 | | 492.62 |
| 3 years | 204.44 | | 492.62 |
| 5 years | 129.64 | | 492.62 |
| 10 years | 74.31 | | 492.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 1996-06-25 | |
| President | 53 | 2016-06-25 | |
James Edgemond
DFI | Director of Finance/CFO | 57 | 2015-03-12 |
| Director | Title | Age | Since |
|---|---|---|---|
Raymond Kurzweil
BRD | Director/Board Member | 77 | 2001-12-31 |
| Chairman | 70 | 1996-06-25 | |
Louis Sullivan
BRD | Director/Board Member | 91 | 2001-12-31 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.06% | 1 M€ | 0.00% | - |
| 2.87% | 2 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.08% | +0.68% | +32.36% | +76.90% | 21.07B | |
| -0.41% | -6.06% | +22.21% | +174.14% | 905B | |
| -0.27% | -2.41% | +35.24% | +14.67% | 487B | |
| -1.15% | -0.71% | +28.32% | +38.09% | 400B | |
| +0.26% | +1.14% | +20.97% | +1.87% | 330B | |
| +0.58% | -2.73% | +27.58% | +21.90% | 281B | |
| +0.19% | +2.49% | +19.23% | +25.56% | 255B | |
| -1.16% | -4.87% | -3.27% | -8.45% | 248B | |
| +1.24% | -2.33% | -60.59% | -30.82% | 214B | |
| -3.02% | -4.51% | +21.03% | +16.45% | 178B | |
| Average | -0.27% | -1.93% | +14.31% | +33.03% | 331.76B | |
| Weighted average by Cap. | -0.36% | -2.77% | +17.71% | +56.98% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.21B 2.76B 2.58B 2.41B 4.44B 289B 4.83B 30.2B 11.66B 136B 12.03B 11.78B 498B | 3.39B 2.91B 2.73B 2.54B 4.7B 305B 5.11B 31.94B 12.33B 144B 12.73B 12.45B 527B |
| Net income | 1.3B 1.12B 1.05B 977M 1.8B 117B 1.96B 12.25B 4.73B 55.3B 4.88B 4.78B 202B | 1.36B 1.17B 1.09B 1.02B 1.88B 122B 2.05B 12.79B 4.94B 57.74B 5.1B 4.99B 211B |
| Net Debt | -3.07B -2.64B -2.47B -2.3B -4.26B -276B -4.63B -28.91B -11.16B -130B -11.52B -11.28B -477B | -4.39B -3.78B -3.54B -3.3B -6.09B -395B -6.62B -41.37B -15.97B -187B -16.49B -16.13B -683B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 489.31 $ | +1.08% | 303,006 |
| 25-12-04 | 484.10 $ | +0.65% | 630,755 |
| 25-12-03 | 480.96 $ | +1.44% | 301,473 |
| 25-12-02 | 474.14 $ | -1.21% | 308,992 |
| 25-12-01 | 479.95 $ | -1.24% | 385,491 |
Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- UTHR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition